Camrelizumab Plus Apatinib and Temozolomide as First-line Treatment in Patients With Advanced Acral Melanoma

In this non-randomized, phase 2 clinical trial, researchers administered camrelizumab, apatinib, and temozolomide to 50 patients with treatment-naive unresectable stage 3 or 4 acral melanoma in an effort to determine the safety of administering this combination as first-line treatment in this patient population.

Access the full article to read more here.